The BD2-selective BET inhibitor apabetalone has been used in trials as a therapy for epigenetic changes, and it has shown that it might decrease cardiovascular risk in individuals with CKD, T2D, and recent acute coronary syndrome and also might modulate the pathways associated with inflammation, vascular calcification, and thrombosis, but the mechanism underlying this benefit is still unclear. Here, DNER is linked to type 2 diabetes mellitus.